Reverse Transcriptase Inhibitors in HIV/AIDS Therapy

1. Front Matter

   Pages i-xiii

   PDF

2. Structural Studies on HIV Reverse Transcriptase Related to Drug Discovery

   • David K. Stammers, Jingshan Ren

   Pages 1-32

3. Zidovudine, Lamivudine, and Abacavir

   • Monica Carten, Harold Kessler

   Pages 33-76

4. Stavudine, Didanosine, and Zalcitabine

   • Gail Skowron, Sapna Chowdhry, Michael R. Stevens

   Pages 77-132

5. Emtricitabine

   • Gail Skowron, Jeffrey Bratberg, Rudi Pauwels

   Pages 133-156

6. Nucleotide Analogs

   • Craig J Hoesley

   Pages 157-178

7. Resistance to Nucleoside and Nucleotide Reverse Transcriptase Inhibitors

   • Nancy Shulman, Mark Winters

   Pages 179-207

8. Pharmacokinetics of Reverse Transcriptase Inhibitors

   • Patrick Hoggard, Stephen Kewn, Saye Khoo, David Back

   Pages 209-236

9. Peripheral Neuropathy Associated With Nucleoside Reverse Transcriptase Inhibitor Therapy

   • Bruce A. Cohen, Russell Bartt

   Pages 237-266

10. Mitochondrial Dysfunction and Nucleoside Reverse Transcriptase Inhibitor Therapy

    • William Lewis

    Pages 267-279

11. Mitochondrial Toxicity and Lipodystrophy

    • Grace McComsey

    Pages 281-302

12. Nevirapine

    • David Asmuth, Richard Pollard

    Pages 303-344

13. Efavirenz

    • Graeme J. Moyle, Brian Conway

    Pages 345-373

14. Delavirdine

    • Brian Conway

    Pages 375-400

15. Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors

    • F. Ramzi Asfour, Richard Haubrich

    Pages 401-424

16. Vertical Transmission of HIV and Therapeutic Interventions

    • Susan Cu-Uvin, Arlene Bardeguez, Carla Chibwesha

    Pages 425-470

17. New Reverse Transcriptase Inhibitors in Development

    • Rudi Pauwels

    Pages 471-497

18. Antiretroviral Drugs for Millions

    • Allan Ronald, Elly Katabira, Merle Sande

    Pages 499-513

19. Back Matter

    Pages 517-527

    PDF

A magisterial survey of all aspects of the reverse transcriptase inhibitors (RTIs) used to treat HIV/AIDS, including drug discovery, pharmacology, development of drug resistance, toxicity, and prevention of mother-to-child transmission of HIV/AIDS. The authors synthesize our current understanding of the role of reverse transcriptase in the viral life cycle, describe the discovery and development of eight nucleoside and nucleotide analogs that represent milestones in treatment history, and thoroughly discuss the question of toxicity and resistance to this class of drugs. They also address three non-nucleoside RTIs and their pharmacokinetics and comparative clinical efficacy, new RTIs currently under development, and the impact of approved agents on treatment, in general, and on vertical transmission in the developing world.

• AIDS
• HIV
• HIV/AIDS
• drug
• drug discovery
• drug resistance
• kinetics
• pharmacokinetics
• pharmacology
• prevention
• resistance
• toxicity
• infectious diseases

From the reviews:

"This book will appeal to medical students needing a detailed review of area … . It is most suitable for libraries … . The individual chapters are authoritative and comprehensive … . a source for in-depth and specific information." (Mark Harris, Microbiology Today, November, 2006)

• National Institute of Allergy and Infectious Diseases National Institutes of Health, USA

  Vassil St.Georgiev

• Division of Infectious Diseases, Roger Williams Medical Center, Providence

  Gail Skowron

• Boston University School of Medicine, Boston

  Gail Skowron

• Pfizer Inc., San Diego

  Richard Ogden

• Center for Poverty-Related Communicable Diseases Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

  Joep M. A. Lange

Policies and ethics